What's new? Log in Free sign up

Forma Therapeutics (FMTX)

Company Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Its R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Its work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Company profile

Ticker

FMTX

Exchange

Website

formatherapeutics.com

CEO

Frank D. Lee

Incorporated

Location

Fiscal year end

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...

Former names

Forma Therapeutics Holdings LLC, Forma Therapeutics Holdings, Inc.,

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Forma Securities Corporation • Forma Therapeutics, Inc. ...

IRS number

371657129

FMTX stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Securities registration termination

Notice of effectiveness

Registration of securities for employees (post-effective amendment)

Prospectus update (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Tender offer solicitation (amended)

Third party tender offer statement (amended)

Exchange delisting

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Brian Andrew Lesser

Jeannette Potts

Wayne A.I. Frederick

ARTURO MD MOLINA

THOMAS G WIGGANS

Financial summary

Financial statements Chart FMTX financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	77.29 mm	77.29 mm	77.29 mm	77.29 mm	77.29 mm	77.29 mm
Cash burn (monthly)	(no burn)	(no burn)	17.67 mm	15.93 mm	14.92 mm	14.17 mm
Cash used (since last report)	n/a	n/a	129.69 mm	116.93 mm	109.54 mm	104.05 mm
Cash remaining	n/a	n/a	-52.40 mm	-39.64 mm	-32.25 mm	-26.75 mm
Runway (months of cash)	n/a	n/a	-3.0	-2.5	-2.2	-1.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

FMTX institutional ownership history Ownership history

94.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	142	108	+31.5%
Opened positions	59	21	+181.0%
Closed positions	25	13	+92.3%
Increased positions	36	41	-12.2%
Reduced positions	29	26	+11.5%

13F shares	Current	Prev Q	Change
Total value	3.07 bn	499.47 mm	+515.1%
Total shares	45.03 mm	46.20 mm	-2.5%
Total puts	272.31 k	66.10 k	+312.0%
Total calls	799.60 k	10.20 k	+7739.2%
Total put/call ratio	0.3	6.5	-94.7%

Largest owners	Shares	Value	Change
Ra Capital Management	9.01 mm	$179.78 mm	0.0%
BLK Blackrock	3.63 mm	$72.46 mm	+16.5%
Lilly Ventures Fund I	2.40 mm	$83.90 mm	0.0%
Baker Bros. Advisors	1.89 mm	$37.64 mm	-6.8%
Vanguard	1.87 mm	$37.21 mm	+13.4%
Novartis Bioventures	1.76 mm	$24.99 mm	0.0%
TIG Advisors	1.31 mm	$26.05 mm	NEW
Water Island Capital	1.25 mm	$25.01 mm	NEW
Alpine Associates Management	1.14 mm	$22.75 mm	NEW
Hillhouse Capital Advisors	1.10 mm	$21.95 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	0.00	-4.74 mm	EXIT
Cormorant Asset Management	0.00	-3.17 mm	EXIT
Deep Track Capital	966.57 k	-3.08 mm	-76.1%
TIG Advisors	1.31 mm	+1.31 mm	NEW
Water Island Capital	1.25 mm	+1.25 mm	NEW
EDBI Pte	55.86 k	-1.21 mm	-95.6%
Alpine Associates Management	1.14 mm	+1.14 mm	NEW
Citadel Advisors	11.22 k	-1.09 mm	-99.0%
Vivaldi Asset Management	1.03 mm	+1.03 mm	NEW
Balyasny Asset Management	1.01 mm	+994.65 k	+8975.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

FMTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Oct 22	Ra Capital Management	Common Stock		Dispose U	Yes	No	0	1,511,425	0.00	0
14 Oct 22	Ra Capital Management	Common Stock		Dispose U	Yes	No	0	7,500,226	0.00	0
14 Oct 22	Ra Capital Management	Common Stock		Dispose U	Yes	No	0	7,250	0.00	0
14 Oct 22	Ra Capital Management	Stock Option Common Stock	Sale back to company	Dispose D	Yes	No	6.12	6,750	41.31 k	0
14 Oct 22	Ra Capital Management	Stock Option Common Stock	Sale back to company	Dispose D	Yes	No	25.35	8,375	212.31 k	0
14 Oct 22	Ra Capital Management	Stock Option Common Stock	Sale back to company	Dispose D	Yes	No	20	17,533	350.66 k	0
14 Oct 22	Fanucci Marsha	Common Stock		Dispose U	No	No	0	7,250	0.00	0
14 Oct 22	Fanucci Marsha	Common Stock		Dispose U	No	No	0	52,532	0.00	0
14 Oct 22	Fanucci Marsha	Stock Option Common Stock	Sale back to company	Dispose D	No	No	6.12	6,750	41.31 k	0
14 Oct 22	Fanucci Marsha	Stock Option Common Stock	Sale back to company	Dispose D	No	No	25.35	8,375	212.31 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.